Ou SH, Kilvert H, Candlish J, Lee B, et al. Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC). Lung Cancer 2024;197:107968.
PMID: 39368244